-
-
-
-
-
-
-
-
-
-
-
-
-
-

Translational medicine (often referred to as translational science, of which it is a form) is defined by the European Society for Translational Medicine (EUSTM) as "an interdisciplinary branch of the biomedical field supported by three main pillars: benchside, bedside, and community". The goal of TM is to combine disciplines, resources, expertise, and techniques within these pillars to promote enhancements in prevention, diagnosis, and therapies. Accordingly, translational medicine is a highly interdisciplinary field, the primary goal of which is to coalesce assets of various natures within the individual pillars in order to improve the global healthcare system significantly.

Translational medicine is a rapidly growing discipline in biomedical research and aims to expedite the discovery of new diagnostic tools and treatments by using a multi-disciplinary, highly collaborative, "bench-to-bedside" approach. Within public health, translational medicine is focused on ensuring that proven strategies for disease treatment and prevention are actually implemented within the community. One prevalent description of translational medicine, first introduced by the Institute of Medicine's Clinical Research Roundtable, highlights two roadblocks (i.e., distinct areas in need of improvement): the first translational block (T1) prevents basic research findings from being tested in a clinical setting; the second translational block (T2) prevents proven interventions from becoming standard practice.

The National Institutes of Health (NIH) has made a major push to fund translational medicine, especially within biomedical research, with a focus on cross-functional collaborations (e.g., between researchers and clinicians); leveraging new technology and data analysis tools; and increasing the speed at which new treatments reach patients. In December 2011, The National Center for Advancing Translational Science (NCATS) was established within the NIH to "transform the translational science process so that new treatments and cures for disease can be delivered to patients faster." The Clinical and Translational Science Awards, established in 2006 and now funded by NCATS, supports 60 centers across the country that provide "academic homes for translational sciences and supporting research resources needed by local and national research communities." According to an article published in 2007 in Science Career Magazine, in 2007 to 2013 the European Commission targeted a majority of its - 6 billion budget for health research to further translational medicine.

Cedars-Sinai Medical Center in Los Angeles, California was accredited in 2012 for a doctoral program in Biomedical Science and Translational Medicine. The PhD program focuses on biomedical and clinical research that relate directly to developing new therapies for patients.

In Fall 2015, the City College of New York established a master in translational medicine program. A partnership between The Grove School of Engineering and the Sophie Davis School for Biomedical Education/CUNY School of Medicine, this program provides scientists, engineers, and pre-med students with training in product design, intellectual property, regulatory affairs, and medical ethics over 3 semesters.

Mahidol University at Faculty of Medicine Ramathibodi hospital has a Master and PhD programme in Translational Medicine since 2012. Mahidol University is the first and only University in Thailand and in Southeast Asia. The most of programme lecturers are physicians and clinicians who contribute in many fields of study such as Cancer, Allergy and Immunology, Haematology, Paediatric, Rheumatology, etc. Here, the student will be directly exposed to patients. To find out the thing in between basic science and clinical application.

The European Society for Translational Medicine (EUSTM) is a global non-profit and neutral healthcare organization whose principal objective is to enhance world-wide healthcare by using translational medicine approaches, resources and expertise. The society facilitates cooperation and interaction among clinicians, scientists, academia, industry, governments, funding and regulatory agencies, investors and policy makers in order to develop and deliver high quality translational medicine programs and initiatives with overall aim to enhance the healthcare of global population. The society's goal is to enhance research and development of novel and affordable diagnostic tools and treatments for the clinical disorders affecting global population.

Academy of Translational Medicine Professionals (ATMP) is working to advance the ongoing knowledge and skills for clinicians and scientific professionals at all levels. Academy’s high quality, standard and ethical training and educational programs ensure that all clinical and scientific professionals achieve excellence in their respective fields. Programs are accredited by the European Society for Translational Medicine (EUSTM).